SCHEMBL2644141

SCHEMBL2644141

CC1(C)Cc2c(O)cc(C(=O)O)cc2O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
MAPT P10636 3/20 0.42
KDM4E B2RXH2 4/20 0.41
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA7 P43166 3/20 0.41
CA9 Q16790 3/20 0.41
CA14 Q9ULX7 3/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CA4 P22748 2/20 0.41
CA6 P23280 2/20 0.41
MAPK1 P28482 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
CA3 P07451 1/20 0.41
SELL P14151 1/20 0.41
SELP P16109 1/20 0.41
FUT4 P22083 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL642957 0.83 LMNA (0.49) ALDH1A1MAPTKDM4ECA12CA1
SCHEMBL15780519 0.77 ALDH1A1 (0.36) ALDH1A1MAPTKDM4EHPGDLMNA
SCHEMBL2643933 0.77 TSHR (0.43) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL19961804 0.74 ALDH1A1 (0.49) ALDH1A1MAPTKDM4ECA12CA1
SCHEMBL643564 0.73 GCK (0.43) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL2644213 0.73 IRAK4 (0.39) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL8940100 0.72 RXRA (0.49) ALDH1A1MAPTKDM4ECA12CA1
SCHEMBL643590 0.72 MAOB (0.49) HPGDSMN1; SMN2RXRA
Cyclolanceaefolic Acid SCHEMBL27831084 0.71 MAPT (0.49) ALDH1A1MAPTKDM4ECA12CA1
SCHEMBL2643997 0.70 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 ALDH1A1 1370/4885MAPT 3264/4885KDM4E 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.